Quality of Life in NSCLC Survivors - A Multicenter Cross-Sectional Study.


Journal

Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer
ISSN: 1556-1380
Titre abrégé: J Thorac Oncol
Pays: United States
ID NLM: 101274235

Informations de publication

Date de publication:
03 2019
Historique:
received: 08 07 2018
revised: 18 11 2018
accepted: 19 11 2018
pubmed: 7 12 2018
medline: 17 4 2020
entrez: 4 12 2018
Statut: ppublish

Résumé

The objective was to assess quality of life (QoL) in lung cancer survivors, compare it to the general population, and identify factors associated with global QoL, physical functioning, emotional functioning, fatigue, pain, and dyspnea. Data from NSCLC patients who had survived 1 year or longer after diagnosis were collected cross-sectionally in a multicenter study. QoL was assessed with the European Organisation for the Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ)-C30 and the lung cancer module QLQ-LC13 across different clinical subgroups and compared to age- and sex-standardized general population reference values. Multivariable linear regression analyses were performed to test the associations of patient-, tumor-, and treatment-related factors with the six primary QoL scales. Six hundred fifty-seven NSCLC patients participated in the study with a median time since diagnosis of 3.7 years (range, 1.0-21.2 years). Compared to the age- and sex-standardized general population, clinically meaningful differences in the QoL detriment were found on almost all domains: lung cancer survivors had clinically relevant poorer global QoL (10 points, p < 0.001). Whereas in 12 months or longer treatment-free patients this detriment was small (8.3), it was higher in patients currently in treatment (16.0). Regarding functioning and symptom scales, respective detriments were largest for dyspnea (41 points), role function (33 points), fatigue (27 points), social function (27 points), physical function (24 points), and insomnia (21 points) observed across all subgroups. The main factor associated with poorer QoL in all primary QoL scales was mental distress (β |19-31|, all p < 0.001). Detriments in QoL across multiple primary QoL scales were also observed with current treatment (β |8-12|, p < 0.01), respiratory comorbidity (β |4-5|, p < 0.01), and living on a disability pension (β |10-11|, p < 0.01). The main factor associated with better QoL in almost all primary QoL scales was higher physical activity (β |10-20|, p < 0.001). Better QoL was also observed in patients with high income (β |10-14|, p < 0.01). Lung cancer survivors experience both functional restrictions and symptoms that persist long term after active treatment ends. This substantiates the importance of providing long-term supportive care.

Identifiants

pubmed: 30508641
pii: S1556-0864(18)33497-X
doi: 10.1016/j.jtho.2018.11.019
pii:
doi:

Types de publication

Journal Article Multicenter Study Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

420-435

Informations de copyright

Copyright © 2018 International Association for the Study of Lung Cancer. Published by Elsevier Inc. All rights reserved.

Auteurs

Marlene Hechtner (M)

University Medical Center, Johannes Gutenberg University, Mainz, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Germany; German Cancer Research Center (DKFZ), Heidelberg, Germany. Electronic address: marlene.hechtner@uni-mainz.de.

Martin Eichler (M)

University Medical Center, Johannes Gutenberg University, Mainz, Germany; German Cancer Consortium (DKTK), partner site Frankfurt/Mainz, Germany; University Hospital Carl Gustav Carus Dresden, Germany.

Beatrice Wehler (B)

University Medical Center, Johannes Gutenberg University, Mainz, Germany; Saarland University Medical Center, Homburg, Germany.

Roland Buhl (R)

University Medical Center, Johannes Gutenberg University, Mainz, Germany.

Martin Sebastian (M)

University Hospital Frankfurt, Goethe University, Frankfurt, Germany.

Jan Stratmann (J)

University Hospital Frankfurt, Goethe University, Frankfurt, Germany.

Heinz Schmidberger (H)

University Medical Center, Johannes Gutenberg University, Mainz, Germany.

Bernhard Gohrbandt (B)

Katholisches Klinikum Mainz, Mainz, Germany.

Jessica Peuser (J)

Katholisches Klinikum Mainz, Mainz, Germany.

Cornelius Kortsik (C)

Katholisches Klinikum Mainz, Mainz, Germany.

Ursula Nestle (U)

University Medical Center Freiburg, Albert-Ludwig-University, Freiburg Germany; Maria Hilf Hospital Moenchengladbach, Moenchengladbach, Germany.

Sebastian Wiesemann (S)

University Medical Center Freiburg, Albert-Ludwig-University, Freiburg Germany.

Hubert Wirtz (H)

Leipzig University Hospital, Leipzig University, Leipzig, Germany.

Thomas Wehler (T)

Saarland University Medical Center, Homburg, Germany.

Robert Bals (R)

Saarland University Medical Center, Homburg, Germany.

Maria Blettner (M)

University Medical Center, Johannes Gutenberg University, Mainz, Germany.

Susanne Singer (S)

University Medical Center, Johannes Gutenberg University, Mainz, Germany; University Cancer Center Mainz, Mainz, Germany.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH